Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from therapeutics

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchenne muscular dystrophy.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market trading after the company announced it will engage in strategic restructuring and cost savings.

e-therapeutics hails "pivotal year" but sees its losses widen

The firm, a spin out from Newcastle University, brings together computing power and biological data to help discovery of new drugs

Birmingham Post

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Newcastle University

Sarepta Therapeutics

Summit Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

297,965 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play